Search
for
Sort by
Research
90-120 / 1000+ results
research Updated Integrated Safety Analysis of Ritlecitinib Over 72 Months In Patients With Alopecia Areata From the ALLEGRO Clinical Trial Program
Ritlecitinib is generally safe for alopecia areata patients over 72 months.
research 42276 Long-Term Safety of Ixekizumab Treatment in Adult Patients with Psoriasis, Psoriatic Arthritis, or Axial Spondyloarthritis: A Post-hoc Analysis of End-Of-Study Program Data Relating to Major Adverse Cardiovascular Events
Ixekizumab is safe for long-term use with low rates of major heart-related events.
research 244 Defective maintenance of hair follicle stem cells through COL17A1 loss orchestrates the hair follicle aging program
Loss of COL17A1 causes hair follicle stem cells to age and leads to hair loss.
research Message from Paul J. McAndrews, Program Chair of the 2010 Annual Meeting
The document's content couldn't be processed to provide a conclusion.
research Message from Paul J. McAndrews, Program Chair of the 2010 Annual Meeting
The document's content couldn't be processed to provide a conclusion.
research Message from Paul J. McAndrews, Program Chair of the 2010 Annual Meeting
research Farmácia dos Clérigos - Porto e nos Serviços Farmacêuticos da University College Hospital - Londres, Reino Unido, ao abrigo do programa Erasmus+
Pharmacists play a crucial role in improving patient outcomes through personalized care and staying updated with scientific advancements.
research 169 TEDAR, a skin-specific long non-coding RNA, orchestrates the late epidermal differentiation program in the human epidermis
TEDAR is crucial for skin cell differentiation and barrier formation.
research Long-Term Efficacy and Complete Scalp Hair Regrowth in Patients With Alopecia Areata Receiving Ritlecitinib 50 mg QD Up to 3 Years in the ALLEGRO Clinical Trial Program
Ritlecitinib 50 mg effectively promotes and sustains hair regrowth in alopecia areata patients.
research Farmácia Monte da Virgem - Vila Nova de Gaia e nos Serviços Farmacêuticos do Hospital Klinica Bolnica Dubrava - Zagreb, Croácia, ao abrigo do programa Erasmus+
research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
research Message from Melvin L. Mayer, MD, Program Chair of the 2011 Annual Meeting
The document's content couldn't be processed for a summary.
research 2P546 Structural Analysis of Curly and Straight Human Hair Fibers by Scanning Microbeam SAXS(52. Bio-imaging,Poster Session,Abstract,Meeting Program of EABS & BSJ 2006)
Curly and straight hair differ in how their internal fibers are arranged.
research Transplantation immunology: Solid organ and bone marrow
Transplant success has improved with better immunosuppressive drugs and donor matching.
research The Many Faces of Calcineurin Inhibitor Toxicity—What the FK?
Calcineurin inhibitors, used in kidney transplants, can cause a wide range of side effects including kidney damage and other health issues.
research Immunosuppressive treatment for proliferative lupus nephritis
Mycophenolate mofetil may improve lupus nephritis remission more than cyclophosphamide but with uncertain safety.
research Spiny Hyperkeratotic Projections on the Face and Extremities of a Kidney Transplant Recipient—Quiz Case
A kidney transplant patient developed pink skin bumps with spiny centers on her face and limbs.
research Cutaneous Toxicities From Transplantation-Related Medications
Skin problems from transplant drugs are common and need careful management in organ transplant patients.
research Three Cases of Alopecia Following Clinical Islet Transplantation
Some patients developed hair loss after islet cell transplant possibly due to their immune-suppressing medications.
research Acne keloidalis nuchae in renal transplant patients receiving tacrolimus and sirolimus
Renal transplant patients on tacrolimus and sirolimus may develop acne keloidalis nuchae.
research P4 Outcome following switch between brand name and generic tacrolimus in paediatric population
Switching to generic tacrolimus was safe, effective, and saved money.
research Trichological disorders in Organ Transplant Recipients - case report and literature review.
Switching immunosuppressants can improve hair regrowth and well-being in transplant patients experiencing hair loss.
research Supplementary Material for: Trichological disorders in Organ Transplant Recipients - case report and literature review.
Switching immunosuppressive drugs can improve hair regrowth and well-being in transplant patients with hair loss.
research Supplementary Material for: Trichological disorders in Organ Transplant Recipients - case report and literature review.
Hair loss from immunosuppressive drugs in transplant patients can affect well-being and treatment adherence, so personalized management is important.
research SIDE EFFECTS OF CYCLOSPORINE COMPARED TO TACROLIMUS AMONG YEMENI KIDNEY TRANSPLANT PATIENTS WHO SHARE THE SAME ADJUVANT AGENTS: MYCOPHENOLATE MOFETIL AND PREDNISONE
Tacrolimus is a better option than cyclosporine due to fewer side effects.
research A case of red lunulae after haematopoietic stem cell transplantation
Adjusting the medication tacrolimus resolved a boy's red nail beds after a stem cell transplant.
research Benign Cutaneous Eruptions After Transplantation
Transplant patients often get skin problems, with treatments varying by condition.
research Calcineurin-based immunosuppression in renal transplantation : focus on efficacy, the role of steroids, and the cardiovascular risk
Tacrolimus causes fewer acute rejections than cyclosporin A in kidney transplants but doesn't necessarily improve kidney function after one year; cardiovascular risks and side effects vary between the two drugs.
research BMP signaling in the control of skin development and hair follicle growth
BMP signaling is crucial for skin and hair growth.